New Guidelines for First-Line Chemo Against Advanced Ovarian Cancer Issued

New Guidelines for First-Line Chemo Against Advanced Ovarian Cancer Issued
According to a new clinical guideline jointly created by the American Society of Clinical Oncology (ASCO) and the Society of Gynecologic Oncology, some women with advanced ovarian cancer should receive neoadjuvant chemotherapy as first-line treatment instead of the standard of care, primary cytoreduction surgery. The guideline was recently published in the Journal of Clinical Oncology, under the title "Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline". Nearly 75 percent of women with ovarian cancer are diagnosed with advanced stage disease (stage IIIC or IV) at presentation. For them, standard of care treatment means primary cytoreductive surgery to reduce the tumor volume as much as possible, followed by chemotherapy. But two recent clinical trials compared the standard care approach with neoadjuvant chemotherapy (NACT) as the first step to shrink the tumor, then followed by interval cytoreductive surgery. The NACT first approach showed lower treatment-related morbidity and mortality, though both were similar in progression-free survival and overall survival. Still, the choice between one treatment or the other remains controversial. The new guidelines provide clinicians with information regarding the use of primary cytoreduction and chemotherapy versus NACT followed by interval cytoreduction for women with stage IIIC or IV epithelial ovarian cancer. The clinical practice guidelines recommend the fo
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *